Compare AbCellera Biologics Inc (ABCL) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Banco Santander SA — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Banco Santander SA trades at $13.59 (market cap $203.67B). The key difference: Banco Santander SA is far larger — about 86.7× AbCellera Biologics Inc's market cap, and Banco Santander SA pays a 1.96% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SAN | |
|---|---|---|
Market Cap | $2.35B | $203.67B |
Sector | Health | Financials |
52-Week High | $8.12 | $14.37 |
52-Week Low | $2.78 | $8.31 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Banco Santander (SAN) trades at $14.19, up 1.72% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.72% net income margin and 16.18% ROE, though recent quarters saw EPS misses. Recent developments include the completion of the TSB acquisition and AI-driven efficiency initiatives, positioning the company for growth amid positive analyst sentiment.
The outlook for SAN is cautiously optimistic, with upside driven by cost-saving measures and strategic acquisitions. Risks include regulatory scrutiny in Spain and volatile cash flows. Analysts maintain a 64% buy rating, highlighting value potential, but investors should monitor execution on profitability targets and macroeconomic impacts on banking sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
